Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Assets (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Assets for 7 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 1.31% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 1.31% year-over-year, with the annual reading at $1.1 billion for FY2025, 1.31% down from the prior year.
  • Assets hit $1.1 billion in Q4 2025 for IDEAYA Biosciences, down from $1.2 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.2 billion in Q3 2024 to a low of $326.1 million in Q1 2021.
  • Historically, Assets has averaged $687.1 million across 5 years, with a median of $530.2 million in 2023.
  • Biggest five-year swings in Assets: surged 220.36% in 2021 and later fell 4.41% in 2025.
  • Year by year, Assets stood at $381.3 million in 2021, then rose by 1.74% to $388.0 million in 2022, then skyrocketed by 67.36% to $649.3 million in 2023, then surged by 73.12% to $1.1 billion in 2024, then fell by 1.31% to $1.1 billion in 2025.
  • Business Quant data shows Assets for IDYA at $1.1 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.0 billion in Q2 2025.